Indus Biotech Private Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Indus Biotech Private Limited - overview
Established
1995
Location
Pune, Maharashtra, India
Primary Industry
Pharmaceuticals
About
Indus Biotech Private Limited is focused on developing innovative healthcare products derived from food chain raw materials, utilizing its patented Natrusolate® technology to enhance health outcomes globally. Founded in 1995 in Pune, India, Indus Biotech specializes in healthcare products, particularly nutraceuticals. The company has secured a total of INR 300. 00 mn in funding from investors like Kotak Alternate Asset Managers, with the latest funding round being a GROWTH round in June 2007.
Keshav Mimani is the founder, who has a history of involvement in health-focused enterprises. Indus Biotech excels in creating nutraceutical ingredients such as Testosurge®, Fenuflakes®, and Vinomerix® through its Natrusolate® technology. These products are designed to support various health outcomes, with Testosurge® clinically validated to increase testosterone levels, while Fenuflakes® offers nutritional support for blood sugar control. The company's offerings extend to Torabolic® and Enducor™, targeting fitness and performance enhancement.
Indus Biotech's global clientele includes manufacturers and retailers engaged in dietary supplements and pharmaceuticals across North America, Europe, and Asia. In 2023, Indus Biotech reported a revenue of INR 7,931,836. 40 with an EBITDA of INR 2,583,182. 80.
The company generates income through direct B2B sales of its nutraceutical products, establishing partnerships with various health and wellness sector businesses to distribute its proprietary ingredients in different formulations, with flagship products like Testosurge® and Torabolic® being central to its revenue streams. Indus Biotech is strategically focusing on developing new nutraceutical products set to launch in the coming years, enhancing its portfolio in health improvement solutions. The company aims to expand into new geographic markets, including targeted regions in Europe and Asia by 2025. The recent funding of INR 300.
00 mn will support these growth initiatives, enhancing research and development capabilities and expanding market reach.
Current Investors
Kotak Alternate Asset Managers
Primary Industry
Pharmaceuticals
Sub Industries
Epidemiology, Pharmaceutical Research & Development
Website
www.indusbiotech.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Indus Biotech Private Limited - financials
| Fiscal Year Ended | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 764,730,000 | 789,240,000 | 331,710,000 | 683,400,000 | 967,130,000 | 679,920,000 | 910,220,000 | 869,950,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 3.2% | (58.0%) | 106.0% | 41.5% | (29.7%) | 33.9% | (4.4%) | - | - | - |
| EBITDA (USD) | 91,878,000 | 484,667,895 | 492,680,000 | 487,930,000 | 116,690,000 | 409,000,000 | 316,240,000 | 865,410,000 | 573,930,000 | (520,400,000) | - | - | - |
| Operating Income (USD) | 65,817,000 | 462,200,000 | 461,960,000 | 450,510,000 | 84,190,000 | 371,450,000 | 276,420,000 | 827,680,000 | 537,140,000 | (568,460,000) | - | - | - |
| Operating Margin | - | - | 60.4% | 57.1% | 25.4% | 54.4% | 28.6% | 121.7% | 59.0% | (65.3%) | - | - | - |
| % EBITDA Margin | - | - | 64.4% | 61.8% | 35.2% | 59.8% | 32.7% | 127.3% | 63.1% | (59.8%) | - | - | - |
| NET Income (USD) | 35,419,512 | 295,841,304 | 315,240,000 | 305,220,000 | 59,880,000 | 277,920,000 | 119,820,000 | 653,260,000 | 343,580,000 | (832,140,000) | - | - | - |
| % Net Margin | - | - | 41.2% | 38.7% | 18.1% | 40.7% | 12.4% | 96.1% | 37.7% | (95.7%) | - | - | - |
Indus Biotech Private Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Indus Biotech Private Limited | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.